Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

NCT01629615 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT01629615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01629615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2015
Enrollment
50 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer